Immatics N.V. Ordinary Shares (IMTX)
Stock · NASDAQ · Health Care
$6.71as of 10/16/2026
Price chart
Active signals
IMTX Signal Track Record
How signals performed across all stocks →What IMTX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 43 | -1.9% | 47% | September 30, 2026 |
| Bollinger Band Breakdown | 24 | +0.4% | 54% | October 2, 2026 |
| Bollinger Band Breakout | 21 | +0.3% | 57% | March 10, 2026 |
| 200-Day Moving Average TouchActive now | 15 | +4.3% | 60% | July 8, 2026 |
| Any 20-session window (baseline) | -0.4% | 48% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About IMTX
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipel…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 704
- Website
- immatics.com/
Fundamentals
- 1-day range
- $6.95$7.2
- Market cap
- $1.26B
- P/E (trailing)
- —
- P/E (forward)
- -3.52
- EPS (trailing)
- $-1.59
- Dividend yield
- —
- Beta
- 1.32
- Avg. volume
- 659.8K
Forecasts
7 analyst ratings
Immatics N.V. Ordinary Shares Competitors
Chosen by industry and closest market cap.
- IMTXImmatics N.V. Ordinary Shares$6.73▼ 5.74%Market cap $1.26BP/E —$6.73$12.41
- INBXInhibrx Biosciences Inc. Common Stock$89.83▼ 0.74%Market cap $1.26BP/E —$28.16$155.29
- NVAXNovavax Inc. Common Stock$11.26▼ 12.17%Market cap $1.27BP/E —$6.2$13.39
- VORVor Biopharma Inc. Common Stock$18.03▼ 6.77%Market cap $1.28BP/E 1.82$6.5$33.42
- GLUEMonte Rosa Therapeutics Inc. Common Stock$9.74▼ 3.75%Market cap $1.33BP/E —$8.94$25.77
- ALVOAlvotech Ordinary Shares$5▼ 5.84%Market cap $1.19BP/E —$2.94$9.05
- MGTXMeiraGTx Holdings plc Ordinary Shares$9.28▼ 6.17%Market cap $1.18BP/E 11.93$6.62$15.35
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IMTX Immatics N.V. Ordinary Shares | $1.26B | — | $6.73 | ▼ 5.74% | $6.73$12.41 |
| INBX Inhibrx Biosciences Inc. Common Stock | $1.26B | — | $89.83 | ▼ 0.74% | $28.16$155.29 |
| NVAX Novavax Inc. Common Stock | $1.27B | — | $11.26 | ▼ 12.17% | $6.2$13.39 |
| VOR Vor Biopharma Inc. Common Stock | $1.28B | 1.82 | $18.03 | ▼ 6.77% | $6.5$33.42 |
| GLUE Monte Rosa Therapeutics Inc. Common Stock | $1.33B | — | $9.74 | ▼ 3.75% | $8.94$25.77 |
| ALVO Alvotech Ordinary Shares | $1.19B | — | $5 | ▼ 5.84% | $2.94$9.05 |
| MGTX MeiraGTx Holdings plc Ordinary Shares | $1.18B | 11.93 | $9.28 | ▼ 6.17% | $6.62$15.35 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- PERCEPTIVE ADVISORS LLC · August 26, 2026 · Buy863.1K @ $8.69
- Pepin James Nelson · August 14, 2026 · Grant43.8K
- Pepin James Nelson · August 14, 2026 · Grant181.2K
- PERCEPTIVE ADVISORS LLC · June 16, 2026 · Grant48.0K
- ATIEH MICHAEL G · June 16, 2026 · Grant48.0K
- Carter Paul Rutherford · June 16, 2026 · Grant48.0K
- Mason Heather L · June 16, 2026 · Grant48.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Stifel initiates Immatics coverage with $15 price target
Stifel began covering Immatics with a Buy rating and a $15 price target, joining a broader wave of new analyst initiations. This new perspective adds to the existing analyst consensus, which currently averages $17.63. The stock is currently trading near its 52-week low, with an RSI of 27.8 indicating oversold conditions.
Stifel initiates Immatics coverage with $15 price target. Stifel began covering Immatics with a Buy rating and a $15 price target, joining a broader wave of new analyst initiations. This new perspective adds to the existing analyst consensus, which currently averages $17.63. The stock is currently trading near its 52-week low, with an RSI of 27.8 indicating oversold conditions.